Generic Imatinib Comparable to Original in Treatment of Chronic Myeloid Leukemia
A retrospective study investigated whether safety and efficacy of generic imatinib is similar to the original form in the treatment of CML.
Diagnosis & Disease Information
Should Age Be a Barrier to Clinical Trial Participation for Older Patients With Metastatic Renal Cell Carcinoma?
A retrospective study compared older patients with mRCC with younger ones to determine if age and potential comorbidities is a barrier to clinical trial participation.
How to Select the Optimal BCR-ABL TKI Therapy for Treatment of Chronic-Phase CML
Key factors that influence choice of TKI for frontline treatment of chronic-phase CML are reviewed, as well as the role for pharmacists in the multidisciplinary oncology care team.
TKI Dose Reduction Improves Treatment-Free Remission Protocols for Chronic Myeloid Leukemia
Study sought to determine the effects of dose reductions in TKI therapy prior to complete cessation improves treatment-free remission in patients with CML.
Patients Have Mixed Responses Regarding Discontinuing TKI Therapy for Chronic Myeloid Leukemia
An interesting finding from this study was that many of the reasons offered by patients either in support of or against TKI discontinuation related to the same topic areas.
Nontypical Formulation of Pazopanib Effective, and Safe With Diligent Monitoring
Two cases studies demonstrate whether crushed pazopanib is a feasible alternative for patients who cannot swallow the tablets whole.
Reasons for TKI Discontinuation ID’d in Chronic Myeloid Leukemia
Treatment-free remission maintained in 14 of 21 patients who discontinued tyrosine kinase inhibitors.
Managing Dermatologic Adverse Events in Patients Receiving Third-Generation EGFR-TKIs
An international team reviews osimertinib-associated dermatologic adverse events in patients treated with the third-generation EGFR-TKI.
De-Escalation or Stoppage May Be Effective After Response to TKI Therapy in CML
De-escalation of TKI therapy may be an effective management strategy among patients with CML who have responded to therapy.
1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML
Although many TKIs have well-documented cardiotoxic effects, results of a single-center prospective study that assessed effects of 1 year of therapy with imatinib or nilotinib in patients with CML demonstrated safety and efficacy of the 2 agents in this population.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...